Metamizole (Analgin) Injection
- Packing: 2 Ml/5 Ml Ampoule.
- Available Strength : 500 Mg/Ml
Description
Product Description: Our Metamizole (Analgin) Injection is a trusted pharmaceutical formulation designed to provide rapid and effective relief from pain and fever. It contains metamizole, a non-opioid analgesic and antipyretic agent, known for its potent pain-relieving properties. Manufactured under strict quality control measures, this injection is widely used in hospitals and healthcare facilities for its reliability and efficacy.
Indications and Usage: Metamizole (Analgin) Injection is indicated for the management of moderate to severe pain, including postoperative pain, visceral pain, and musculoskeletal pain. Additionally, it is used for the treatment of fever associated with various medical conditions.
Dosage and Administration: The dosage of Metamizole (Analgin) Injection varies depending on the patient's age, weight, and severity of pain or fever. It is administered via intramuscular or slow intravenous injection under the supervision of a qualified healthcare professional. Dosage adjustments may be necessary based on the patient's response to therapy and individual tolerance.
Dosage Forms and Strengths: Metamizole (Analgin) Injection is available in vials containing a specific concentration of metamizole formulated for parenteral administration. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.
Contraindications: This product is contraindicated in patients with a known hypersensitivity to metamizole or any of the excipients. It should not be used in patients with a history of agranulocytosis or other blood dyscrasias associated with metamizole use. Additionally, it is contraindicated in patients with a history of severe hepatic or renal impairment.
Warnings and Precautions: Healthcare providers should exercise caution when prescribing Metamizole (Analgin) Injection to patients with a history of asthma, urticaria, or other allergic reactions. Prolonged use may lead to the development of agranulocytosis, a potentially life-threatening condition characterized by severe neutropenia. Patients should be monitored closely for signs of agranulocytosis during therapy.
Adverse Reactions/Side Effects: Common adverse reactions associated with Metamizole (Analgin) Injection include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. Rarely, serious adverse effects such as agranulocytosis, aplastic anemia, and severe skin reactions may occur. Patients should be advised to report any unusual symptoms promptly.
Drug Interactions: Concomitant use of Metamizole (Analgin) Injection with other drugs that inhibit bone marrow function or metabolism may increase the risk of hematological toxicity. Healthcare providers should review the patient's medication profile carefully to avoid potential drug interactions.
Use In Specific Populations Description: Safety and efficacy of Metamizole (Analgin) Injection in pediatric patients, pregnant women, and nursing mothers have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.
How Supplied/Storage and Handling: Metamizole (Analgin) Injection is supplied as a sterile solution in vials for parenteral administration. It should be stored at controlled room temperature away from light and moisture. Care should be taken to avoid freezing or excessive heat exposure. Unused portions should be discarded according to standard procedures for biohazardous waste.
